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present that histologic lesions of TG are 
reversible with therapy, whether this be 
removal of DSA, treatment of HCV, lower-
ing of CNI dose, or other treatment, and 
once TG is apparent by light microscopy, 
the fate of the graft  may already be sealed. 
 Indeed, an important key to prolonging 
graft  survival would appear to be preven-
tion of TG, and in this regard, recognizing 
those graft s at high risk for developing TG 
is an important step toward this goal. Our 
fi ndings in patients with DSA, glomerulitis, 
and / or peritubular capillaritis, and early 
ultrastructural findings that have been 
reported in graft s that later develop TG, 3 
suggest that early treatment with intrave-
nous immunoglobulin, plasmapheresis, 
and / or rituximab may prevent or at least 
delay the onset of TG. 14 By expanding the 
list of potential etiologies of TG, Baid-
Agrawal and co-workers 10 have opened the 
door for studies of early treatment of other 
potential causes of TG, particularly HCV. 
It will also be important to determine 
whether there are specifi c subsets of HCV-
positive allograft recipients who are at 
greatest risk for developing TG, just as 
DSAs against human leukocyte antigen 
class II antigens are most closely associated 
with TG. 2,5 For example, does HCV-associ-
ated TG occur signifi cantly more oft en, 
or earlier post-transplantation, when there 
is also evidence of TMA? If so, might 
the presence of anti-cardiolipin antibodies 
represent an important risk factor for 
development of TG in these patients? Are 
HCV-positive graft  recipients treated with 
CNI-sparing immunosuppressive regimens 
less likely to develop TG than patients 
receiving standard doses of CNIs? 
 In summary, it is important for us to 
recog nize that TG is not a specifi c diagno-
sis that can be equated with chronic or 
chronic-active AMR but is rather a pattern 
of graft injury with a number of non-
mutually-exclusive etiologies that now 
include HCV and TMA in addition to 
AMR. More importantly, we can now focus 
even more on determining which patients 
among those with alloantibody, HCV, 
and / or TMA are at greatest risk for devel-
oping TG and why, and what can be done 
therapeutically to reduce this risk. 
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 Olfactory function in dialysis 
patients: a potential key to 
understanding the uremic state 
 Andrew S.  Bomback 1 and  Amanda C.  Raff 2 
 Impaired olfactory function is a marker of neurologic dysfunction in 
the uremic state. Retained uremic toxins not adequately cleared with 
dialysis may undermine the integrity of the olfactory epithelium and 
olfactory bulb and malign central olfactory processing. The evidence 
suggests that only renal transplantation, with its concomitant thorough 
reversal of uremia, truly restores olfactory function to normal in end-
stage renal disease. Testing of olfactory function may emerge as an 
important marker for the extent and resolution of uremia. 
 Kidney International (2011)  80, 803 – 805.  doi: 10.1038/ki.2011.219 
see original article on page 886
 1 Division of Nephrology, Department of 
Medicine, Columbia University College of Physicians 
and Surgeons ,  New York ,  New York ,  USA and  
 2 Department of Medicine, Albert Einstein College 
of Medicine and Montefiore Medical Center ,  Bronx , 
 New York ,  USA 
 Correspondence: Andrew S. Bomback, Columbia 
University Medical Center, 622 West 168th Street, 
Ph 4-124, New York, New York 10032, USA.  
 E-mail:  asb68@columbia.edu 
 Th e excessive morbidity and mortality 
that affl  icts the end-stage renal disease 
(ESRD) population on maintenance dial-
ysis has received signifi cant attention in 
both the medical and the mass-market 
literature. While these depressing statistics 
should by no means be ignored, what 
oft en strikes dialysis providers rounding 
in outpatient units is the poor day-to-day 
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quality of life that many ESRD patients 
endure. Depression and anxiety are com-
mon comorbid conditions in ESRD popu-
lations, affecting up to 30 % of dialysis 
patients. 1 Malnutrition and anorexia are 
even more prevalent, aff ecting up to 75 % 
of patients with ESRD. Other indicators of 
neurologic dysfunction, running the 
gamut from restless legs syndrome and 
peripheral neuropathy to generalized 
weakness and cognitive decline, 
are increasingly recognized as key con-
tributors to the morbidity of daily life 
as an ESRD patient. 2 Prospective data 
showing positive eff ects of increased dial-
ysis frequency on composite end points of 
death, left  ventricular hypertrophy, and 
physical health score, 3 coupled with the 
even more profound benefi ts of transplan-
tation for these parameters, suggest that 
persistent uremia is the underlying pro-
cess behind the poor outcomes in dialysis 
populations. Unfortunately, our current 
ability to assess uremia and adequacy of 
dialysis remains substandard, relying on 
subjective clinical histories and inconsist-
ent laboratory parameters. 
 Impaired olfactory function may serve 
as an easily quantifi ed measure of neuro-
logic dysfunction in the ESRD population 
and open a new window on our under-
standing of uremia. Richard Axel and 
Linda Buck were awarded the Nobel Prize 
in Physiology or Medicine in 2004 for 
their work elucidating the structure and 
function of the mammalian olfactory sys-
tem ( Figure 1 ). Both the peripheral olfac-
tory epithelial neurons and the higher 
central processing pathways can be 
aff ected in uremia. Th e neurons of the 
olfactory epithelium are constantly regen-
erated throughout the lifespan, and thus 
any toxin that slows or halts cell growth 
can impair olfaction. 4 Toxins that damage 
the intrinsic antioxidant system of the 
olfactory epithelium and olfactory bulb 
have also been shown to significantly 
decrease olfaction. 5 Retained uremic tox-
ins, small molecules not adequately 
cleared with current dialysis technologies 
or treatment schedules, could theoreti-
cally be responsible for impaired olfaction 
in ESRD patients by undermining the 
regeneration of olfactory neurons and / or 
disrupting maintenance of redox homeo-
stasis that is crucial for normal function 
of the olfactory epithelium and olfactory 
bulb. Uremic toxins or alterations in hor-
monal or osmotic homeostasis could also 
aff ect central olfactory processing. 
 Previous studies have yielded interest-
ing, but oft en confl icting, results regarding 
olfaction, uremia, and malnutrition. 6 – 9 
These small studies have uniformly 
reported reduced olfactory function in 
ESRD patients but have diverged in 
whether the impairment is in odor iden-
tifi cation, discrimination, and / or thresh-
old. Moreover, the eff ect of dialysis on this 
impaired olfaction has been even more 
inconsistent, with some studies reporting 
improvement, others reporting no change, 
and still others showing a slight worsening 
of function aft er dialysis. Only one study 
has examined the eff ect of transplantation 
on olfactory function, reporting full res-
toration of olfaction after surgery, 7 an 
important fi nding that further implicates 
the uremic state, which theoretically can 
only be suffi  ciently reversed with success-
ful transplantation, in the pathogenesis of 
impaired olfactory function. Correlations 
between nutritional status and olfactory 
function in ESRD patient samples have 
been suggested but not reliably shown. 
Finally, only one study has attempted to 
explore the association of uremic toxins 
and olfactory dysfunction in ESRD 
patients; it found no correlation between 
diminished olfactory identifi cation and 
four measured uremic toxins. 9 
 Th e report from Landis and colleagues 10 
(this issue) on olfactory function in dialy-
sis patients therefore adds another impor-
tant contribution to this growing fi eld. 
Th ese investigators compared olfactory 
function in 20 hemodialysis patients, 8 
peritoneal dialysis patients, and 24 healthy 
control subjects by testing odor identifi ca-
tion (12 common odors, such as orange, 
peppermint, and coff ee) and thresholds 
( n -butanol and acetic acid). Both perito-
neal dialysis and hemodialysis patients 
performed worse than healthy controls in 
identifi cation and acetic acid threshold 
tests, but not in  n -butanol threshold tests. 
Test scores also suggested a trend of 
poorer performance among hemodialysis 
compared with peritoneal dialysis patients, 
although small sample sizes limit this 
comparison, as does a substantial diff er-
ence in dialysis vintage between these 
groups (mean 25.3 months for the perito-
neal dialysis group versus 126.6 months 
for the hemodialysis group). Interestingly, 











 Figure 1  |  Humans express over 300 different olfactory receptors. Each olfactory neuron 
expresses only one receptor, but each receptor can bind more than one odorant. Olfactory neurons 
synapse with mitral cells in glomerular clusters in the olfactory bulb; the mitral cells subsequently 
project to higher centers in the limbic system and cerebral cortex, allowing humans to identify 
millions of unique odorants. Landis  et al. 10 present data suggesting that olfactory dysfunction in 
dialysis patients occurs both at the peripheral level (olfactory receptor) and at higher processing 
centers (cerebral cortex). 
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diff erent between healthy controls and 
dialysis subjects, highlighting the silent 
nature of this impairment as well as the 
potential pitfalls in relying on subjective 
metrics of uremic parameters. 
 The study is also noteworthy in its 
reporting of improvements in overall 
olfactory score just 1  h aft er a single hemo-
dialysis session. The improvement was 
greatest in odor identification, which 
climbed to normal range, whereas thresh-
old levels rose more modestly. Th e study is 
strengthened by its use of multiple 
olfactory tests, which may explain why 
these investigators were able to detect 
 improvements in olfaction aft er hemodi-
alysis whereas prior studies, using only 
one testing modality, have not shown 
improvement with dialysis. Th e authors 
attempted to test for a learning eff ect by 
repeating odor identifi cation testing within 
4 hours for both hemodialysis patients and 
healthy controls. Although neither group 
showed further improvements, a more 
thorough investigation could include con-
tinuous testing of dialysis subjects in the 
interdialytic period. A gradual reversal of 
the olfactory improvements from pre- to 
postdialysis back to predialysis levels over 
a 48-hour interdialytic period would both 
disprove a learning eff ect and further high-
light the role of uremic toxins, at least the 
ones that can be cleared by dialysis, in the 
pathogenesis of impaired olfaction. 
 Like many small but innovative studies, 
the report from Landis and colleagues 10 
raises more questions than it defi nitively 
answers. Th e mean ( ± standard deviation) 
normalized protein catabolic rates 
(nPCRs) for hemodialysis and peritoneal 
dialysis subjects were 0.95 ± 0.04  g / kg / d 
and 0.96 ± 0.07  g / kg / d, respectively; there-
fore, the investigators reported no link 
between olfactory function and nutri-
tional status. A larger sample size that 
included patients with a wider range of 
nPCR values or additional measures of 
nutritional status might allow for identi-
fi cation of a more subtle link between our 
current metrics for nutrition and olfactory 
testing. One of the most interesting fea-
tures of this report is that, by testing both 
threshold and identifi cation, the authors 
are able to speculate that impaired olfac-
tion of ESRD patients stems from defects 
in both central (refl ected by identifi cation 
performance) and peripheral (refl ected by 
threshold performance) nervous path-
ways. Th ese data would be enhanced by 
administration of standardized cognitive 
testing alongside olfactory testing. 
 Th e authors reported small diff erences 
between olfactory function in hemodialy-
sis subjects and that in peritoneal dialysis 
subjects that may, speculatively, refl ect 
more adequate renal replacement therapy 
in the latter population. As is mentioned 
above, these results could stem more from 
diff erences in dialysis vintage rather than 
modality. Another potential way to assay 
for the eff ects of adequacy of dialysis dos-
ing would be to compare olfactory per-
formance of thrice-weekly hemodialysis 
patients against daily or nocturnal hemo-
dialysis patients. Th e numerous, ongoing 
studies on more frequent dialysis, includ-
ing the multicenter randomized studies 
currently conducted by the Frequent 
Hemodialysis Network Trials Group, 
should consider adding olfactory testing 
to their protocols. 
 Despite numerous advances in our care 
and management of the ESRD population 
over the past two decades, the overall 
prognosis for new-start hemodialysis 
patients remains essentially unchanged 
and unacceptably poor. Th e grim statistics 
on morbidity and mortality in dialysis 
patients are matched by equally grim 
reports on inferior quality of life in this 
group. Observational data suggest that 
inadequate dialysis and a persistent ure-
mic state contribute to these poor out-
comes, but we still lack reliable ways to 
measure this phenomenon. Olfactory test-
ing may emerge as a simple but informa-
tive metric for chronic dialysis patients: a 
surrogate marker used to search for the 
underlying causes of uremic neurologic 
dysfunction and, ultimately, to identify 
improved treatments for uremia. 
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